Showing 8731-8740 of 20877 results for "".
Calming Overactive Immune Response and Reducing Inflammation with TYK2 Inhibition in Psoriasis
https://reachmd.com/programs/cme/calming-overactive-immune-response-and-reducing-inflammation-with-tyk2-inhibition-in-psoriasis/50978/Join us to learn about the emerging data with TKY2 inhibitors for treatment of psoriasis.Practical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 4
https://reachmd.com/programs/practical-dermatology/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-4/56872/In the fourth installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, focus on how adjuvant skincare may influence treatment pathways, including delaying or optimizing escalation to systemic therapies.1 Draelos Z, HoSurvey Says: Aligning Early Advanced IBD Therapy with Patient Priorities
https://reachmd.com/programs/cme/survey-says-aligning-early-advanced-ibd-therapy-with-patient-priorities/57916/On-demand webcast on the latest advances in managing inflammatory bowel disease (IBD) and expert-informed strategies for providing guideline-concordant care to patients with IBD.Innovations in Precision Medicine: Leveraging Guideline-Based Immunotherapy and Targeted Treatments in Gynecologic Oncology
https://reachmd.com/programs/cme/Innovations-in-Precision-Medicine-Leveraging-Guideline-Based-Immunotherapy-and-Targeted-Treatments-in-Gynecologic-Oncology/37235/Multidisciplinary experts explore biomarker-driven strategies, immunotherapy, and personalized care in cervical and endometrial cancer management.DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
https://reachmd.com/clinical-practice/oncology-hematology/destiny-breast11-trastuzumab-deruxtecan-followed-by-thp-yields-new-indication-in-the-neoadjuvant-setting/57280/DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.Identifying and Managing Adult Patients with Chronic Immune Thrombocytopenia
https://reachmd.com/programs/medical-industry-feature/adult-chronic-immune-thrombocytopenia-management/56537/Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts and increased bleeding risk, and can have significant impacts on patients’ quality of life.1 Treatment decisions require a personalized approach that considers both clinical factors and patient prefeImproving Sleep and Mental Health in Patients with CKD-aP
https://reachmd.com/programs/cme/improving-sleep-and-mental-health-in-patients-with-ckd-ap/36301/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.ASCVD Playbook | Closing the Gaps, One Inning at a Time
https://reachmd.com/programs/cme/ascvd-playbook-closing-the-gaps-one-inning-at-a-time/54284/Step up to the plate with evidence-based strategies to identify patients with high-risk ASCVD, optimize LDL-C, and up your game in secondary prevention.The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Breaking the Cycle: Understanding and Managing Inflammatory Memory in Psoriasis
https://reachmd.com/programs/clinicians-roundtable/breaking-the-cycle-understanding-and-managing-inflammatory-memory-in-psoriasis/32446/Inflammatory memory may influence symptom recurrence in psoriasis patients. Learn about how it works and strategies for promoting sustained remission.